H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price target of $10.00. The company's shares closed last Tuesday at $1.62, close to its 52-week low of $1.26. According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.6% and a 31.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clearside Biomedical with a $9.67 average price target, a 523.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-clearside-biomedicals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Clearside Biomedical Charts.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Clearside Biomedical Charts.